CEL-SCI CEO Geert Kersten to Be Interviewed Live Today on Clear Channel Business Talk Radio
March 25 2014 - 10:26AM
Marketwired
CEL-SCI CEO Geert Kersten to Be Interviewed Live Today on Clear
Channel Business Talk Radio
Interview Scheduled at 11:05am PDT / 12:05 pm MDT / 2:05pm EDT
on the Traders Network Radio Show, Hosted by Michael Yorba
VIENNA, VA--(Marketwired - Mar 25, 2014) - CEL-SCI Corporation
(NYSEMKT: CVM), a leading research and development company
dedicated to improving the treatment of cancer and other diseases
by utilizing the immune system, today announced that CEO Geert
Kersten will be interviewed live today by host Michael Yorba on
Clear Channel Business Talk Radio's The Traders Network
Show. Any interested parties may tune in and listen live
via Clear Channel's nationally syndicated iHeart Radio stream.
The live interview details are as follows:
Date: Tuesday, March 25, 2014 Start Time: 11:05am
PDT | 12:05pm MDT | 2:05pm EDT (U.S.)
Network: Clear Channel Station: DFW 1190AM KFXR
Show: The Traders Network Host: Michael Yorba Live iHeart
Radio Stream: http://www.iheart.com/live/4276/?autoplay=true
About Clear Channel: Clear Channel's Media and Entertainment
division has the largest reach of any radio or television outlet in
America with 243 million monthly listeners. It serves 150 cities
through 850 owned radio stations in the U.S., as well as more than
140 stations in New Zealand and Australia.
www.clearchannel.com.
About Michael Yorba: Mr. Yorba is the founder of Yorba Media and
featured host on Clear Channel. For the past six years he has
produced and hosted The Traders Network Show broadcasted live daily
on Clear Channel DFW 1190AM KFXR from 1pm - 3pm CT,
Monday-Friday.
Michael Yorba interviews the front-page Titans about the latest
in capital markets, CEO milestones, trading tools, real estate
acquisitions and market trends. Learn how the experts use risk
management techniques to build fully diversified portfolios and
what it takes to put up big board earnings. It's a fast moving,
high-energy show that presents stocks, commodities, bonds, forex,
derivatives, real estate, political trends, technology trends,
crowd funding and impact investment insights in a new light and
keeps audience asking for more... shift your thinking and join us
as we deliver "tomorrow's ideas today" on Clear Channel's The
Traders Network Show.
About CEL-SCI: CEL-SCI is dedicated to research and development
directed at improving the treatment of cancer and other diseases by
utilizing the immune system, the body's natural defense
system. Its lead investigational therapy is Multikine
(Leukocyte Interleukin, Injection), currently being studied in a
pivotal Phase III clinical trial against head and neck cancer.
CEL-SCI also has an ongoing collaboration with the US Navy to
develop Multikine as a treatment against anal warts in HIV/HPV
co-infected patients. CEL-SCI is further investigating an
immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1
hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid
Arthritis (currently in preclinical testing) using its LEAPS
technology platform. The investigational immunotherapy
LEAPS-H1N1-DC treatment involves non-changing regions of H1N1
Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI
scientists are very concerned about the possible emergence of a new
more virulent hybrid virus through the combination of H1N1 and
Avian Flu, or maybe Spanish Flu. The Company has operations in
Vienna, Virginia, and in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
Multikine is the trademark that CEL-SCI has registered for
this investigational therapy, and this proprietary name is subject
to FDA review in connection with its future anticipated regulatory
submission for approval. Multikine has not been licensed or
approved for sale, barter or exchange by the FDA or any other
regulatory agency. Similarly, its safety or efficacy has not been
established for any use. Moreover, no definitive conclusions can be
drawn from the early-phase, clinical-trials data involving the
investigational therapy Multikine (Leukocyte Interleukin,
Injection). Further research is required, and early-phase clinical
trial results must be confirmed in the well-controlled, Phase III
clinical trial of this investigational therapy that is currently in
progress.
When used in this release, the words "intends," "believes,"
"anticipated" and "expects" and similar expressions are intended to
identify forward-looking statements. Such statements are subject to
risks and uncertainties which could cause actual results to differ
materially from those projected. Factors that could cause or
contribute to such differences include, an inability to duplicate
the clinical results demonstrated in clinical studies, timely
development of any potential products that can be shown to be safe
and effective, receiving necessary regulatory approvals,
difficulties in manufacturing any of the Company's potential
products, inability to raise the necessary capital and the risk
factors set forth from time to time in CEL-SCI Corporation's SEC
filings, including but not limited to its report on Form 10-K for
the year ended September 30, 2013. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
A www.1800PublicRelations.com PR
Event
Contacts: CEL-SCI Corporation Contact: Gavin de Windt +1 (703)
506-9460 Press/Media Contact: Matthew Bird MUNCmedia Public
Relations +1 (917) 409-8211 matt.bird@muncmedia.com
www.muncmedia.com
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2023 to Apr 2024